Sofinnova Partners – a leading European life sciences venture capital firm based in Paris, London, and Milan – recently announced the successful closing of Sofinnova Digital Medicine I at $200 million (€190M), significantly exceeding its target. The fund – which Partners Edward Kliphuis and Simon Turner spearheaded – is focused on backing pioneering entrepreneurs navigating the convergence of biology, data, and computation. It has already invested in five revolutionary companies since its inception.
Sofinnova’s Digital Medicine Strategy comes at an essential time when the healthcare sector is undergoing a significant transformation aided by digital advancements. And the fund targets three main areas: enabling technologies, analytics, and treatment. This provides entrepreneurs with financial backing, expertise, and deeply-rooted healthcare networks, empowering them to address global healthcare challenges and enhance patient outcomes worldwide.
The two most recent additions to the Sofinnova Digital Medicine portfolio include:
– L’école AI – the creator of a “machine teaching” technology and established by an ex-Twitter Cortex founding team member, simplifying the deployment of deep-learning systems for computer vision in life sciences applications.
– Betteromics – the “Omics AI Cloud” unifies disparate health and omics data into a single source of truth through a certified SaaS platform backed by the expertise of its founding team from GRAIL, Verily, and Google’s Search Knowledge Graph.
KEY QUOTES:
“The successful closing of Sofinnova Digital Medicine I above its target size marks yet another milestone in our growth as a global firm fostering disruptive innovations in life sciences. This newest fund in our platform of investment strategies is a testament to the trust our limited partners place in our vision and to Sofinnova’s longstanding commitment to shaping the future of healthcare.”
— Antoine Papiernik, Sofinnova’s Chairman and Managing Partner
“In just a few months since launching this strategy, we’ve executed five investments into transformative companies, including Kiro, BioCorteX, deepc, L’école AI, and Betteromics, which are fusing state-of-the-art computational methods with advanced biological innovations. Leveraging Sofinnova’s expertise and network, we serve as allies to digital medicine pioneers, enabling them to secure product-market fit and scale on a global stage.”
— Edward Kliphuis, Partner
“We bring Sofinnova’s deep healthcare expertise to entrepreneurs pioneering at the forefront of digital medicine where biology meets tech-industry approaches like rapid product iteration and accelerated commercialization. Our goal is to support innovators developing disruptive solutions for patients and health systems.”
— Simon Turner, Partner
